Sep 2026· Journal of Medicinal Chemistry· Vol 69 19, pp.
21653-21672
· 0 citations· 103 references
Medicine
TL;DR
This perspective critically evaluates recent advances in the development of small-molecule anti-SFTSV agents, organized through a dual framework encompassing both viral life cycle targets and host-dependent pathways.
Abstract
Severe fever with thrombocytopenia syndrome virus (SFTSV), an emerging tick-borne bunyavirus with a case fatality rate of up to 30%, poses a growing threat to global public health. No approved specific antivirals are currently available. This perspective critically evaluates recent advances in the development of small-molecule anti-SFTSV agents, organized through a dual framework encompassing both viral life cycle targets and host-dependent pathways. We highlight direct-acting antivirals targeting key viral components, including viral entry glycoproteins (Gc/Gn proteins), cap-snatching endonuclease, RNA-dependent RNA polymerase (RdRp), and nucleoprotein (NP), as well as host-directed therapies modulating critical cellular pathways. Notable candidates include the clinical-stage prodrug VV261 and calcium channel blockers with proven in vivo efficacy and retrospective clinical evidence. By integrating molecular mechanistic insights with translational progress, this perspective provides a comprehensive reference for accelerating the development and clinical translation of small-molecule therapeutics against SFTSV.
A comprehensive overview of ZIKV pathogenesis, transmission routes, and molecular mechanisms underlying host–virus interactions is provided, with emphasis on structural and functional insights into key viral enzymes NS2B–NS3 protease and NS5 RNA-dependent RNA polymerase which serve as pivotal antiviral drug targets.
Arvind Kumar, Harpreet Singh, Sagar Varshney et al.· Chemical biology letters· 0 citations
Host receptor targeting is a mechanistically rational but still clinically unproven component of the respiratory antiviral landscape; its value is most plausibly realised in defined niches—prophylaxis, early outpatient treatment, and combination with direct-acting antivirals—and within pandemic preparedness frameworks,...
S. El-Kafrawy, Norah A. Othman, M. Zeyadi et al.· Frontiers in Cellular and In...· 0 citations
Rhinovirus is the main pathogen causing common colds, acute exacerbations of asthma, chronic obstructive pulmonary disease and other respiratory diseases. Due to its numerous serotypes and the lack of common conserved viral targets, the development of traditional direct-acting antiviral drugs (DAAs) faces challenges. H...
Wanru Shang, Hongbing Luo, Siqi Li et al.· Frontiers in Immunology· 0 citations
This narrative review critically analyses the principal molecular targets of DENV, including structural proteins (C, prM/M and E), nonstructural proteins (NS1–NS5) and host factors, with emphasis on the development of small‐molecule antivirals and an evaluation of their progress in pre‐clinical and clinical studies.
Aryane Lucia da Silva Aguiar De Oliveira, José Arion da Silva Moura, Pedro César de Souza et al.· ChemistrySelect· 0 citations
This review examines the principles and applications of target-based antiviral drug development against human respiratory viruses, emphasizing the identification and exploitation of conserved viral and host targets.
S. K. Samrat, Gaurie Srivastava, Ran Zhang et al.· Pathogens· 0 citations
The human monoclonal antibody MR191N provides complete post-exposure protection in non-human primates and necessitates adaptive trial designs, expanded diagnostic models, and synergistic combination therapies to address MVD.
V. Kandi, F. Branda, Mohammed Alissa et al.· Expert Review of Anti-Infect...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.